Cargando…

HGG-08. COMBINATORIAL ACTIVITY OF CDK4/6-INHIBITORS AND TRAMETINIB IN PEDIATRIC HIGH-GRADE GLIOMA WITH BRAFV600E MUTATION AND HOMOZYGOUS CDKN2A DELETION

BRAFV600E mutations occur in 10-15% and homozygous CDKN2A deletions in approximately 40% of adolescent and pediatric high-grad glioma (HGG) and is associated with significantly decreased overall survival. Moreover, a subset of pHGG is defined by combined BRAFV600E mutation and concomitant CDKN2A hom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayr, Lisa, Mager, Leah, Gabler, Lisa, Madlener, Sibylle, Berger, Julia, Kirchhofer, Dominik, Lämmerer, Anna, Bruckner, Katharina, Lötsch, Daniela, Berger, Walter, Gojo, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: High Grade Glioma/Gliomatosis Cerebri - HGG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260149/ http://dx.doi.org/10.1093/neuonc/noad073.157

Ejemplares similares

HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
por: Trissal, Maria, et al.
Publicado: (2023)

HGG-24. A NOVEL ONCOGENIC ROLE FOR MENIN IN GLIOMA
por: Yang, Yanhong, et al.
Publicado: (2023)

HGG-02. METABOLIC TARGETING OF HIGH-GRADE GLIOMAS WITH MTAP LOSS
por: Subramaniam, Bavani, et al.
Publicado: (2023)

HGG-04. INFANTILE HIGH GRADE GLIOMA: HONG KONG EXPERIENCE
por: Ning Lau, Sarah Sau, et al.
Publicado: (2023)

HGG-05. PERTURBING GABAERGIC NEURONAL LINEAGE IN DIFFUSE HEMISPHERIC GLIOMA, H3G34-MUTANT, HIGHLIGHTS CDK6 AS A CLINICALLY ACTIONABLE TARGET
por: Liu, Ilon, et al.
Publicado: (2023)

HGG-17. SINGLE-CELL AND SPATIAL ANALYSES DECIPHER THE UNIQUE INVASIVE GROWTH PATTERN OF GLIOMATOSIS CEREBRI
por: Crampsie, Shauna, et al.
Publicado: (2023)

HGG-12. INFANT HEMISPHERIC GLIOMA: CLINICAL AND MOLECULAR CHARACTERISTICS AND RESULTS OF TARGETED THERAPY
por: Papusha, Ludmila, et al.
Publicado: (2023)

HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
por: Hu, Wanming, et al.
Publicado: (2023)

HGG-06. CHARACTERIZATION OF THE EFFECT OF THE ORAL IRON-MIMETIC GALLIUM MALTOLATE ON PEDIATRIC GLIOBLASTOMA GROWTH IN VIVO
por: Al-Gizawiy, Mona M, et al.
Publicado: (2023)

HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS
por: Johnson, Theodore S, et al.
Publicado: (2023)

HGG-15. HIGH-GRADE GLIOMAS OCCURRING IN TEENAGERS AND YOUNG ADULT PATIENTS COMPRISE NOVEL MOLECULAR SUBGROUPS
por: Clarke, Matthew, et al.
Publicado: (2023)

HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES
por: Yenidogan, Irem, et al.
Publicado: (2023)

HGG-21. ABERRANT SPLICING OF CLK1 IN PEDIATRIC HIGH-GRADE GLIOMAS DISRUPTS KEY ONCOGENIC TRANSCRIPTIONAL PROGRAMS
por: Naqvi, Ammar, et al.
Publicado: (2023)

HGG-07. OVEREXPRESSION OF A PLAG-FAMILY TRANSCRIPTION FACTOR DURING MURINE BRAIN DEVELOPMENT CAUSES BRAIN TUMOR FORMATION
por: Vaillant, Jan, et al.
Publicado: (2023)

HGG-14. RAS PATHWAY MEDIATED REGULATION OF HISTONE METHYLTRANSFERASE AND TUMOR SUPPRESSOR SETD2 IN PEDIATRIC HIGH GRADE GLIOMA
por: Liou, Angela, et al.
Publicado: (2023)

HGG-13. ONCOGENIC STAT3 AND SHP2 ACTIVATION IN ROS1-FUSION DRIVEN INFANT-TYPE HEMISPHERIC GLIOMAS
por: Postlmayr, Andreas, et al.
Publicado: (2023)

HGG-20. NOVEL PAEDIATRIC CASE OF A SPINAL HIGH-GRADE ASTROCYTOMA WITH PILOID FEATURES IN A PATIENT WITH NOONAN SYNDROME
por: Staunton, Jordan, et al.
Publicado: (2023)

HGG-23. DECIPHERING THE RELATIONSHIP OF MICROSATELLITE-INSTABILITY AND MUTATIONAL BURDEN IN HIGH-GRADE GLIOMA PATIENTS WITH CONSTITUTIONALLY IMPAIRED DNA DAMAGE RESPONSE
por: Blattner-Johnson, Mirjam, et al.
Publicado: (2023)

HGG-03. HIGH-GRADE GLIOMA IN YOUNG CHILDREN IS HISTOLOGICALLY, MOLECULARLY, AND CLINICALLY DIVERSE—RESULTS FROM THE SJYC07 TRIAL AND INSTITUTIONAL EXPERIENCE
por: Chiang, Jason, et al.
Publicado: (2023)

HGG-27. THE IMPACT OF MISMATCH REPAIR DEFICIENCY ON GLIOMAS IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS; A REPORT FROM THE IRRDC AND THE GLIOMA TASK FORCE
por: Negm, Logine, et al.
Publicado: (2023)

HGG-22. PROGNOSTIC FACTORS FOR PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH NON-DIPG GRADE 4 GLIOMAS: A CONTEMPORARY POOLED INSTITUTIONAL EXPERIENCE
por: Matsui, Jennifer, et al.
Publicado: (2023)

HGG-11. APPLICATION OF SHUNT IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA COMPLICATED WITH HYDROCEPHALUS: A 10-YEAR EXPERIENCE FROM A SINGLE CENTER
por: Cai, Linbo, et al.
Publicado: (2023)

HGG-09. GLIOMATOSIS CEREBRI IN CHILDREN: A POOR PROGNOSTIC, HIGHLY INFILTRATIVE PHENOTYPE OF DIFFUSE PEDIATRIC HIGH-GRADE GLIOMAS WITH DISTINCT MOLECULAR FEATURES
por: Nussbaumer, Gunther, et al.
Publicado: (2023)

HGG-25. TARGETED DRUGS SYNERGIZE WITH DOUBLE ALKYLATOR THERAPY IN H3.3 G34R/V PEDIATRIC HIGH-GRADE GLIOMA
por: Haase, Rebecca, et al.
Publicado: (2023)

HGG-26. GENOMIC AND IMMUNE ANALYSIS OF PRIMARY REPLICATION-REPAIR DEFICIENT (RRD) GLIOMAS REVEALS THREE SUBGROUPS WITH DISTINCT DRIVERS AND RESPONSE TO IMMUNOTHERAPY: AN IRRDC REPORT
por: Fernandez, Nicholas R, et al.
Publicado: (2023)

HGG-10. A SAFETY AND EFFICACY STUDY OF NOVOTTF-100A FOR PEDIATRIC HIGH-GRADE GLIOMA: RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE FIRST THREE CASES
por: Makimoto, Atsushi, et al.
Publicado: (2023)

HGG-18. SINGLE CELL RNA-SEQ ANALYSIS OF PEDIATRIC HIGH-GRADE GLIOMA PATIENT SAMPLES IDENTIFIES COMMON GLIAL AND IMMUNE CELL TYPES THAT HELP TO EXPLAIN HETEROGENEITY AND TUMORIGENESIS
por: DeSisto, John, et al.
Publicado: (2023)

HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations
por: Laemmerer, Anna, et al.
Publicado: (2022)

HGG-47. DECREASED GROWTH VELOCITY WITH LONG TERM USE OF BRAFV600e AND MEK INHIBITION IN A PATIENT WITH ANAPLASTIC GANGLIOGLIOMA
por: Tran, Hung, et al.
Publicado: (2020)

HGG-37. UPFRONT TARGETED THERAPY FOR THE TREATMENT OF BRAFV600E-MUTANT PEDIATRIC HIGH-GRADE GLIOMA – A MULTI-INSTITUTIONAL EXPERIENCE
por: Rosenberg, Tom, et al.
Publicado: (2021)

HGG-29. A CASE OF CIRCUMSCRIBED HIGH-GRADE ASTROCYTOMA WITH ATRX AND CDKN2A/B ALTERNATIONS WHO WAS INITIALLY DIAGNOSED AS GLIOBLASTOMA AND HAS 20 YEARS SURVIVAL
por: Kobayashi, Yusuke, et al.
Publicado: (2020)

HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas
por: Boynton, Adam, et al.
Publicado: (2022)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

HGG-29. How I treat recurrent pediatric high-grade glioma (HGG): A Europe-wide survey study.
por: Perwein, Thomas, et al.
Publicado: (2022)

HGG-58. SIOPE HGG Working Group approach to obtain consensus on management of paediatric high grade glioma across Europe
por: Giraud, Géraldine, et al.
Publicado: (2022)

HGG-16. EXOSOME-MEDIATED INTER-CLONAL INTERACTIONS IN PEDIATRIC GBM AND DIPG
por: Pericoli, Giulia, et al.
Publicado: (2020)

HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA
por: Liu, Ilon, et al.
Publicado: (2021)

HGG-31. UNIQUE BIOLOGICAL CHARACTERISTICS OF RADIATION-INDUCED GLIOMAS
por: Váňová, Kateřina, et al.
Publicado: (2020)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

HGG-33. EXPLOITING METABOLIC DEFECTS WITH NAMPT INHIBITORS IN DIPG
por: Muraleedharan, Ranjithmenon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rio07auor8189jt2bvs8fdm7vv